Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Caplin Point Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, March 04, 2020, to consider and approve the payment of Interim Dividend for the financial year 2019-2020. Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the record date for determining the eligibility of the shareholders for the payment of Interim Dividend for the financial year 2019-2020, will be Friday, March 13, 2020. Further, the Trading Window for dealing in the equity shares of the Company shall remain closed for Promoters, Directors, other Connected Persons and Employees of the Company from February 28, 2020 to March 06, 2020 as per the Company's Code of Conduct to regulate, monitor and report trading by insiders adopted by the Board pursuant to SEBl (Prohibition of Insider Trading) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: